Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Eur J Cancer
    October 2025
  1. MERCOLINI F, Sparber-Sauer M, Mascarenhas L, Merks JHM, et al
    Single site metastatic rhabdomyosarcoma: An INternational Soft Tissue saRcoma ConsorTium (INSTRuCT) pooled analysis.
    Eur J Cancer. 2025;229:115793.
    >> Share

    September 2025
  2. WEBENDOERFER M, Wiesweg M, Winantea J, Keyl J, et al
    Early years, advanced disease: The unmet need in young adults with non-small cell lung cancer.
    Eur J Cancer. 2025;230:116011.
    >> Share

  3. PRABHASH K, Noronha V, Patil V, Menon N, et al
    Response to Letter Re: "A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer".
    Eur J Cancer. 2025;230:115802.
    >> Share

  4. LIU Y, Wang L, Li L, He L, et al
    Comment on: "A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer".
    Eur J Cancer. 2025;230:115801.
    >> Share

  5. BYUN JY, Kim J, Park S, Sun JM, et al
    A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer.
    Eur J Cancer. 2025;230:115805.
    >> Share

  6. SHIRAISHI Y, Shimose T, Tachihara M, Tsuchiya-Kawano Y, et al
    Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).
    Eur J Cancer. 2025;229:115779.
    >> Share

  7. MURO K, Feinstein T, Baranda J, Bonta I, et al
    Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study.
    Eur J Cancer. 2025;227:115603.
    >> Share

  8. GALLINA FT, Marinelli D, Taje R, Visca P, et al
    TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma.
    Eur J Cancer. 2025;227:115622.
    >> Share

    August 2025
  9. TSUKAGUCHI A, Matsumoto K, Tamiya A, Tamiya M, et al
    Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study.
    Eur J Cancer. 2025;228:115748.
    >> Share

  10. ITALIANO A, Gautier O, Dupont J, Assi T, et al
    The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients.
    Eur J Cancer. 2025;226:115609.
    >> Share

  11. YAMAGUCHI K, Takao S, Kanaji N, Hirakawa T, et al
    The clinical potential of HMGB1 for the risk assessment of severe checkpoint inhibitor pneumonitis: A prospective multicenter study (CS-Lung004).
    Eur J Cancer. 2025;226:115606.
    >> Share

  12. PRABHASH K, Noronha V, Patil V, Menon N, et al
    A randomized trial of patient navigation with symptom-monitoring in advanced lung cancer.
    Eur J Cancer. 2025;228:115730.
    >> Share

  13. NAGASHIMA H, Fukuhara T, Utsumi Y, Suzuki A, et al
    A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
    Eur J Cancer. 2025;229:115693.
    >> Share

    July 2025
  14. MONACA F, Gomez-Randulfe I, Walls G, Cantale O, et al
    Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.
    Eur J Cancer. 2025;225:115592.
    >> Share

  15. GOBBINI E, Langlais A, Missy P, Chanoine S, et al
    Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS.
    Eur J Cancer. 2025;225:115560.
    >> Share

  16. YIP R, Mulshine JL, Oudkerk M, Field J, et al
    Current evidence of low-dose CT screening benefit.
    Eur J Cancer. 2025;225:115570.
    >> Share

  17. LINARDOU H, Papadopoulou K, Korfiatis N, Goussia A, et al
    Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final outcome, immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.
    Eur J Cancer. 2025;228:115660.
    >> Share

  18. PARK GH, Park S, Kim H, Jung HA, et al
    Prospective investigation of biomarker and resistance mechanism using longitudinal cell-free NGS in non-small cell lung cancer with EGFR exon 20 insertion treated with amivantamab.
    Eur J Cancer. 2025;226:115631.
    >> Share

  19. ALEXANDER M, Cheng Y, Lee SH, Passaro A, et al
    Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
    Eur J Cancer. 2025;227:115624.
    >> Share

  20. RECK M, Paz-Ares LG
    Response to the letter Re: "Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial".
    Eur J Cancer. 2025;226:115610.
    >> Share

  21. KUSCHE H, Gundler C, Johanns O, Sauerberg M, et al
    Leveraging machine-learning techniques to detect recurrences in cancer registry data: A multi-registry validation study using German lung cancer data.
    Eur J Cancer. 2025;227:115604.
    >> Share

  22. SCATTOLIN D, Dingemans AC, Maso AD, Guarneri V, et al
    Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort.
    Eur J Cancer. 2025;226:115595.
    >> Share

    June 2025
  23. O'REILLY D, O'Grady A, Hayes C, Piggott L, et al
    Clinical benefit and cost of plasma-first next-generation sequencing in patients with newly diagnosed advanced non-small cell lung cancer in Ireland: The PLAN study.
    Eur J Cancer. 2025;225:115582.
    >> Share

  24. LAGUNA JC, Moreno L, Potrony M, Grau E, et al
    Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis.
    Eur J Cancer. 2025;225:115571.
    >> Share

    May 2025
  25. MONACA F, Gomez-Randulfe I, Parreira AS, Longo V, et al
    Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.
    Eur J Cancer. 2025;221:115435.
    >> Share

  26. AIGNER C, Baldes N, Begic M, Doerr F, et al
    Current perspective on resectability in stage III locally advanced NSCLC - The thoracic surgeons' view.
    Eur J Cancer. 2025;221:115426.
    >> Share

  27. VAN KESSEL E, Woerdman N, Pluim D, Kerklaan BM, et al
    Added prognostic value of circulating tumor cell numbers in CSF of patients with leptomeningeal metastasis from epithelial tumors.
    Eur J Cancer. 2025;220:115377.
    >> Share

  28. GRAUS MUJE, van Diepen AE, Josemanders K, Besselink MG, et al
    Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based study.
    Eur J Cancer. 2025;220:115385.
    >> Share

    April 2025
  29. AGRAWAL M, Surendran AK, Biswas R
    Letter Re: Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Eur J Cancer. 2025 Apr 23:115442. doi: 10.1016/j.ejca.2025.115442.
    >> Share

  30. KIM S, Ahn Y, Lee GD, Choi S, et al
    Validation of the 9th Tumor, Node, and Metastasis Staging System for Patients with Surgically Resected Non-Small Cell Lung Cancer.
    Eur J Cancer. 2025;222:115436.
    >> Share

    March 2025
  31. CORTIULA F, Kutiel TS, Hsu ML, Hendriks LEL, et al
    Comparative efficacy of immunotherapy-based treatment versus chemotherapy-only in patients with unresectable NSCLC with disease progression post chemoradiation and durvalumab.
    Eur J Cancer. 2025;219:115302.
    >> Share

  32. SALVESTRINI V, Bonaparte I, Becherini C, Desideri I, et al
    Stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Long-term clinical outcome and favorable predictive factors.
    Eur J Cancer. 2025;218:115260.
    >> Share

  33. MULSHINE JL, Avila RS, Sylva M, Aldige C, et al
    AI integrations with lung cancer screening: Considerations in developing AI in a public health setting.
    Eur J Cancer. 2025;220:115345.
    >> Share

    February 2025
  34. WANG HY, Liao WY, Ho CC, Wu SG, et al
    Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.
    Eur J Cancer. 2025;217:115224.
    >> Share

  35. LANCASTER HL, Jiang B, Davies MPA, Gratama JWC, et al
    Histological proven AI performance in the UKLS CT lung cancer screening study: Potential for workload reduction.
    Eur J Cancer. 2025;220:115324.
    >> Share

  36. LANCASTER HL, Walstra ANH, Myers K, Avila RS, et al
    Action plan for an international imaging framework for implementation of global low-dose CT screening for lung cancer.
    Eur J Cancer. 2025;220:115323.
    >> Share

  37. HAN R, Guo H, Shi J, Wang H, et al
    Corrigendum to "Tumour microenvironment changes after osimertinib treatment resistance in non-small cell lung cancer" [Eur J Cancer 189 (2023) 112919].
    Eur J Cancer. 2025 Feb 20:115307. doi: 10.1016/j.ejca.2025.115307.
    >> Share

  38. WALSTRA ANH, Lancaster HL, Heuvelmans MA, van der Aalst CM, et al
    Corrigendum to: Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: Impact on negative-misclassifications and clinical referral rate, European Journal of Cancer, Volume 216, 5 February 2025, 115214.
    Eur J Cancer. 2025;218:115294.
    >> Share

  39. WISLEZ M, Mascaux C, Cadranel J, Thomas QD, et al
    Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.
    Eur J Cancer. 2025;219:115301.
    >> Share

  40. BORG M, Lokke A, Ibsen R, Hilberg O, et al
    Four decades of lung cancer: Trends in comorbidities and causes of death in a nationwide Danish cohort.
    Eur J Cancer. 2025;218:115303.
    >> Share

  41. YANKELEVITZ DF, Yip R, Jirapatnakul A, Henschke CI, et al
    The Winner and still champion: Nodule volume doubling times.
    Eur J Cancer. 2025;216:115184.
    >> Share

    January 2025
  42. MULSHINE JL, Pyenson B, Healton C, Aldige C, et al
    Paradigm shift in early detection: Lung cancer screening to comprehensive CT screening.
    Eur J Cancer. 2025;218:115264.
    >> Share

  43. ACKER F, Reck M, Martin D, Rieken S, et al
    Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis.
    Eur J Cancer. 2025;218:115266.
    >> Share

  44. LAKTIONOV K, Smolin A, Stroyakovskiy D, Moiseenko V, et al
    Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.
    Eur J Cancer. 2025;217:115255.
    >> Share

  45. SAAL J, Eckstein M, Ritter M, Brossart P, et al
    The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression.
    Eur J Cancer. 2025;215:115163.
    >> Share

  46. HONG TH, Hwang S, Abbosh C, Dasgupta A, et al
    Association of pre-surgical circulating tumor DNA detection, use of sublobar resection with risk of recurrence in stage I non-small cell lung cancer.
    Eur J Cancer. 2025;217:115237.
    >> Share

    December 2024
  47. WALSTRA ANH, Lancaster HL, Heuvelmans MA, van der Aalst CM, et al
    Feasibility of AI as first reader in the 4-IN-THE-LUNG-RUN lung cancer screening trial: impact on negative-misclassifications and clinical referral rate.
    Eur J Cancer. 2024;216:115214.
    >> Share

  48. LEE SM, Hewish M, Ahmed S, Papadatos-Pastos D, et al
    Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial.
    Eur J Cancer. 2024;215:115162.
    >> Share

  49. TANAKA H, Makiguchi T, Tozuka T, Kawashima Y, et al
    Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
    Eur J Cancer. 2024;213:115117.
    >> Share

    November 2024
  50. PATEL AJ, Hemead H, Law J, Wali A, et al
    Impact of the timing of immunotherapy administration on overall survival for resectable non-small cell lung cancer (iACORN study): A systematic review and meta-analysis of randomised trials.
    Eur J Cancer. 2024;214:115118.
    >> Share

  51. ALSHAMMARI A, Patel A, Boyle M, Proli C, et al
    Prevalence of invasive lung cancer in pure ground glass nodules less than 30 mm: A systematic review.
    Eur J Cancer. 2024;213:115116.
    >> Share

  52. DERNBACH G, Kazdal D, Ruff L, Alber M, et al
    Dissecting AI-based mutation prediction in lung adenocarcinoma: A comprehensive real-world study.
    Eur J Cancer. 2024;211:114292.
    >> Share

  53. VELUT Y, Arque B, Wislez M, Blons H, et al
    The tumor immune microenvironment of SCLC is not associated with its molecular subtypes.
    Eur J Cancer. 2024;212:115067.
    >> Share

  54. ZHOU Q, Yang N, Zhao M, Huang D, et al
    Potent covalent irreversible inhibitor of KRAS G12C IBI351 in patients with advanced solid tumors: First-in-human phase I study.
    Eur J Cancer. 2024;212:114337.
    >> Share

    October 2024
  55. SAALFELD FC, Moller J, Christopoulos P, Wenzel C, et al
    Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
    Eur J Cancer. 2024;213:115065.
    >> Share

  56. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024 Oct 2:115057. doi: 10.1016/j.ejca.2024.115057.
    >> Share

    September 2024
  57. BENJAMIN DJ, Prasad V
    Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer.
    Eur J Cancer. 2024;212:115058.
    >> Share

  58. TSUCHIYA-KAWANO Y, Shiraishi Y, Tanaka K, Tachihara M, et al
    Nivolumab plus ipilimumab with chemotherapy for non-small cell lung cancer with untreated brain metastases: A multicenter single-arm phase 2 trial (NIke, LOGiK 2004).
    Eur J Cancer. 2024;212:115052.
    >> Share

  59. RECK M, Granados ALO, de Marinis F, Meyers O, et al
    Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.
    Eur J Cancer. 2024;212:115050.
    >> Share

  60. KANG H, Do W, Ahn YC, Chie EK, et al
    A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation.
    Eur J Cancer. 2024;212:115043.
    >> Share

  61. JIANG B, Han D, van der Aalst CM, Lancaster HL, et al
    Lung cancer volume doubling time by computed tomography: A systematic review and meta-analysis.
    Eur J Cancer. 2024;212:114339.
    >> Share

  62. HOCHMAIR MJ, Vermaelen K, Mountzios G, Carcereny E, et al
    Sotorasib (960 mg or 240 mg) once daily in patients with previously treated KRAS G12C-mutated advanced NSCLC.
    Eur J Cancer. 2024;208:114204.
    >> Share

  63. NIKOLAOU V, Gerochristou M, Sgontzou T, Silaidi C, et al
    Beneath the surface: Novel insights into Amivantamab-induced acneiform rash.
    Eur J Cancer. 2024;208:114198.
    >> Share

  64. XIE M, Chu T, Dong X, Wang H, et al
    Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors.
    Eur J Cancer. 2024;209:114260.
    >> Share

  65. BAUM P, Cardoso R, Lenzi J, Damhuis RAM, et al
    An International Registry Study of Early-Stage NSCLC treatment variations (LUCAEUROPE) in Europe and the USA highlighting variations.
    Eur J Cancer. 2024;209:114233.
    >> Share

    August 2024
  66. RECK M, Ciuleanu TE, Schenker M, Bordenave S, et al
    Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
    Eur J Cancer. 2024;211:114296.
    >> Share

  67. FALCHERO L, Meyer N, Molinier O, Al Freijat F, et al
    Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting.
    Eur J Cancer. 2024;210:114277.
    >> Share

  68. LIU SY, Erazo T, Jee J, Arfe A, et al
    Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.
    Eur J Cancer. 2024;210:114257.
    >> Share

  69. ZHU H, Wang FL, Liu JR
    Letter Re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024 Aug 8:114267. doi: 10.1016/j.ejca.2024.114267.
    >> Share

  70. KRON A, Scheffler M, Wiesweg M, Hummel HD, et al
    Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Eur J Cancer. 2024;207:114158.
    >> Share

  71. TOUBLANC AC, Faure M, Verdy G, Rabeau A, et al
    Prospective cardiovascular events in patients with advanced thoracic cancer treated with immune checkpoint inhibitor.
    Eur J Cancer. 2024;207:114191.
    >> Share

    July 2024
  72. DE NIJS K, de Koning HJ, van der Aalst C, Ten Haaf K, et al
    Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021).
    Eur J Cancer. 2024;208:114231.
    >> Share

  73. PARK S, Park S, Kim TM, Kim S, et al
    Resistance mechanisms of EGFR tyrosine kinase inhibitors, in EGFR exon 20 insertion-mutant lung cancer.
    Eur J Cancer. 2024;208:114206.
    >> Share

  74. DE JAGER VD, Cajiao Garcia BN, Kuijpers CCHJ, de Bock GH, et al
    Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.
    Eur J Cancer. 2024;205:114125.
    >> Share

  75. REBUZZI SE, Fornarini G, Banna GL, Rescigno P, et al
    Letter comments on: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Eur J Cancer. 2024;205:114097.
    >> Share

    June 2024
  76. ANDERSEN L, Kisistok J, Henriksen TV, Bramsen JB, et al
    Exploring the biology of ctDNA release in colorectal cancer.
    Eur J Cancer. 2024;207:114186.
    >> Share

  77. KUBOTA S, Taki T, Miyoshi T, Tane K, et al
    Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma.
    Eur J Cancer. 2024;207:114184.
    >> Share

  78. FELIP E, Metro G, Soo RA, Wolf J, et al
    Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancer.
    Eur J Cancer. 2024;208:114182.
    >> Share

  79. CARRIL-AJURIA L, Lavaud P, Dalban C, Negrier S, et al
    Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma.
    Eur J Cancer. 2024;204:114048.
    >> Share

    May 2024
  80. LUKE JJ, Long GV, Robert C, Carlino MS, et al
    Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non-small cell lung cancer, and renal cell carcinoma.
    Eur J Cancer. 2024;207:114146.
    >> Share

  81. BLASI M, Kuon J, Luders H, Misch D, et al
    Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
    Eur J Cancer. 2024 May 24:114130. doi: 10.1016/j.ejca.2024.114130.
    >> Share

  82. LAM M, Olivier T, Haslam A, Tuia J, et al
    Cisplatin shortage results in substitution of more expensive treatments: Drug cost analysis.
    Eur J Cancer. 2024;202:114019.
    >> Share

  83. HERTZ DL, Joerger M, Bang YJ, Mathijssen RH, et al
    Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations.
    Eur J Cancer. 2024;202:114024.
    >> Share

  84. CAO H, Ma Z, Huang Q, Han H, et al
    Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
    Eur J Cancer. 2024;202:113985.
    >> Share

  85. HAAKENSEN VD, Ojlert AK, Thunold S, Farooqi S, et al
    UV1 telomerase vaccine with ipilimumab and nivolumab as second line treatment for pleural mesothelioma - A phase II randomised trial.
    Eur J Cancer. 2024;202:113973.
    >> Share

    April 2024
  86. KATSUMATA S, Shimokawa M, Hamada A, Haratake N, et al
    Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
    Eur J Cancer. 2024;201:113951.
    >> Share

    March 2024
  87. LEONETTI A, Perrone F, Puntoni M, Maglietta G, et al
    Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
    Eur J Cancer. 2024;202:114006.
    >> Share

  88. CATOZZI S, Assaad S, Delrieu L, Favier B, et al
    Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study.
    Eur J Cancer. 2024;199:113571.
    >> Share

  89. BRAHMER JR, Long GV, Hamid O, Garon EB, et al
    Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.
    Eur J Cancer. 2024;199:113530.
    >> Share

  90. WANG M, Wang T, Shan J, Sun Y, et al
    Alectinib induced vitiligo with rapid re-pigmentation.
    Eur J Cancer. 2024;200:113582.
    >> Share

  91. GOMEZ-RANDULFE I, Leporati R, Gupta B, Liu S, et al
    Recent advances and future strategies in first-line treatment of ES-SCLC.
    Eur J Cancer. 2024;200:113581.
    >> Share

    February 2024
  92. STRATMANN JA, Althoff FC, Doebel P, Rauh J, et al
    Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
    Eur J Cancer. 2024;201:113911.
    >> Share

  93. MARK M, Froesch P, Gysel K, Rothschild SI, et al
    First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
    Eur J Cancer. 2024;200:113600.
    >> Share

  94. EBSTEIN E, Brocard P, Soussi G, Khoury R, et al
    Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study.
    Eur J Cancer. 2024;200:113604.
    >> Share

  95. CHIANG Y, Lu LF, Tsai CL, Tsai YC, et al
    C-C chemokine receptor 4 (CCR4)-positive regulatory T cells interact with tumor-associated macrophages to facilitate metastatic potential after radiation.
    Eur J Cancer. 2024;198:113521.
    >> Share

    January 2024
  96. BLASI M, Kuon J, Luders H, Misch D, et al
    First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
    Eur J Cancer. 2024;199:113556.
    >> Share

  97. OLIVIER T, Addeo A
    Shrinking sample sizes in lung cancer trials: Various explanations, open questions.
    Eur J Cancer. 2024;199:113527.
    >> Share

  98. JANKU F, Kim TM, Iyer G, Spreafico A, et al
    First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations.
    Eur J Cancer. 2024;196:113458.
    >> Share

  99. BELDERBOS RA, Corneth OBJ, Dumoulin D, Hendriks RW, et al
    Atypical B cells (CD21-CD27-IgD-) correlate with lack of response to checkpoint inhibitor therapy in NSCLC.
    Eur J Cancer. 2024;196:113428.
    >> Share

  100. DE MIGUEL-PEREZ D, Pickering EM, Malapelle U, Grier W, et al
    Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
    Eur J Cancer. 2024;196:113457.
    >> Share

  101. SCHALLENBERG S, Dernbach G, Dragomir MP, Schlachtenberger G, et al
    TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading.
    Eur J Cancer. 2024;197:113474.
    >> Share

  102. WATANABE S, Furuya N, Nakamura A, Shiihara J, et al
    A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study).
    Eur J Cancer. 2024;197:113469.
    >> Share

    December 2023
  103. STEMMER A, Margalit O, Serpas V, Strauss G, et al
    Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Eur J Cancer. 2023;198:113495.
    >> Share

  104. REMON J, Lopez A, Planchard D, Besse B, et al
    Are we ready to escalate or de-escalate immune treatment strategies in NSCLC based on liquid biopsy data?
    Eur J Cancer. 2023;195:113369.
    >> Share

  105. BOSI C, Bartha A, Galbardi B, Notini G, et al
    Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response.
    Eur J Cancer. 2023;195:113379.
    >> Share

    November 2023
  106. WENG PC, Huang YL, Cheng CY
    Osimertinib-induced urticarial vasculitis in a patient with lung cancer: A rare cutaneous toxicity.
    Eur J Cancer. 2023;196:113432.
    >> Share

  107. FAKIH M, Wang C, Sandhu J, Ye J, et al
    Immunotherapy response in microsatellite stable metastatic colorectal cancer is influenced by site of metastases.
    Eur J Cancer. 2023;196:113437.
    >> Share

  108. RATAIN MJ, Strohbehn GW
    Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
    Eur J Cancer. 2023;194:113349.
    >> Share

    October 2023
  109. NUCCIO A, Viscardi G, Salomone F, Servetto A, et al
    Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategi
    Eur J Cancer. 2023;195:113404.
    >> Share

  110. YAMADA T, Goto Y, Tanaka H, Kimura H, et al
    A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
    Eur J Cancer. 2023;195:113373.
    >> Share

  111. LEARY A, Oaknin A, Trigo JM, Moreno V, et al
    Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours.
    Eur J Cancer. 2023;192:113259.
    >> Share

    August 2023
  112. YANG CY, Shih JY, Liao WY, Ho CC, et al
    Upfront liquid next-generation sequencing in treatment-naive advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
    Eur J Cancer. 2023;193:113310.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016